Pistol Ribozyme-Driven Catalytic Spherical Nucleic Acid Integrates Gene and Chemotherapy for Enhanced Cancer Therapy

Area of Science:

• Biotechnology and Nanomedicine
• Molecular Biology
• Cancer Therapeutics

Background:

• Gene-targeted therapies, including ribozymes, show promise for cancer treatment due to specificity and low toxicity.
• Pistol ribozymes are effective RNA silencers but face challenges like nuclease susceptibility and poor delivery.
• Spherical nucleic acid (SNA) nanocarriers offer a stable platform for delivering nucleic acid-based therapeutics.

Purpose of the Study:

• To develop an innovative gene-regulation strategy for cancer treatment.
• To overcome the delivery limitations of engineered pistol ribozymes.
• To create a dual-action nanoplatform combining gene therapy and chemotherapy.

Main Methods:

• Engineered pistol ribozymes were incorporated into a spherical nucleic acid (SNA) nanocarrier with doxorubicin (Dox).
• The nanocarrier, named ApRz-CS/Dox, featured a DNA core-shell structure with tumor-targeting aptamers.
• The system was designed to release the ribozyme in response to miR-21 for polo-like kinase 1 mRNA cleavage.

Main Results:

• The ApRz-CS/Dox nanoplatform demonstrated enhanced stability and tumor-targeting capabilities.
• The engineered ribozyme successfully cleaved polo-like kinase 1 mRNA within target cancer cells.
• The combined gene therapy and doxorubicin treatment showed synergistic anti-cancer effects.

Conclusions:

• The catalytic SNA nanocarrier effectively delivers engineered pistol ribozymes for targeted gene silencing.
• This integrated approach addresses challenges in nucleic acid drug delivery and enhances cancer treatment efficacy.
• The ApRz-CS/Dox nanoplatform represents a promising strategy for combined gene and chemotherapeutic cancer treatment.